allogeneic CD19-specific T cells

Allogeneic CD19-specific T cells are an adoptive cell therapy involving the genetic modification of T cells derived from a healthy donor (typically the same donor providing hematopoietic stem cells for the patient) to express a chimeric antigen receptor (CAR) or specific receptor targeting the CD19 antigen. CD19 is a cell surface protein ubiquitously expressed on B-lineage cells, including those involved in B-cell leukemias and lymphomas. By engineering these donor-derived T cells to recognize CD19, the therapy aims to provide a targeted graft-versus-leukemia (GVL) effect. This approach is primarily investigated as a modified donor lymphocyte infusion (DLI) for patients with advanced B-cell malignancies following allogeneic hematopoietic stem cell transplantation (HSCT), aiming to eliminate residual disease or treat relapse while monitoring for potential graft-versus-host disease (GVHD).

Other names

Donor-derived CD19-specific T cellsAllogeneic CD19 CAR T-cellsModified donor lymphocyte infusionCD19-specific T-cellsCD-19-specific T-cellsCD 19-specific T-cells